Bruno Coudert
机构: Centre Georges Francois Leclerc Dijon France
每年引用次数
引用次数
引用: 17,349
H-指数: 60
I10-指数 : 124
出版物: 426
Pharmacokinetics of amiodarone in the isolated rat lung.
P Camus , B Coudert , M Dumas , L Jeannin
Journal of Pharmacology and Experimental Therapeutics 254 ( 1) 336 -343
16
1990
Pharmacokinetics and metabolism of nilutamide in the isolated rat lung.
P Camus , B Coudert , J Delchambre , L Jeannin
Journal of Pharmacology and Experimental Therapeutics 259 ( 3) 1247 -1255
8
1991
Serum concentrations of amiodarone required for an in vivo modulation of anthracycline resistance.
B Chauffert , P Genne , F Martin , B Coudert
Anticancer Research 9 ( 6) 1655 -1659
10
1989
Hepatic arterial infusion of cisplatin diluted in hypotonic 25 g/l glucose solution administered in balloon-occluded hepatic artery: experimental rationale and clinical pilot study.
B Chauffert , N Isambert , S Zanetta , P Fargeot
Journal of Experimental & Clinical Cancer Research 20 ( 2) 183 -188
3
2001
Yellow nail syndrome. A new etiology of restrictive respiratory insufficiency
P Camus , B Coudert , L Jeannin , J P Dumas
La Nouvelle presse médicale 11 ( 36) 2711
1982
Comparison of relative survival vs. classical survival. Apropos of primary bronchial cancer
P Arveux , P Camus , B Coudert , D Dramais-Marcel
Bulletin Du Cancer 81 ( 10) 857 -865
3
1994
[Phase II trial with cystemustine (60 mg/m2) in advanced or metastatic pretreated lung carcinoma].
P Chollet , M Lentz , B Coudert , B Chevallierdagger
Revue De Pneumologie Clinique 56 ( 3) 200 -203
1
2000
T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival
S Ladoire , L Arnould , G Mignot , L Apetoh
British Journal of Cancer 105 ( 3) 366 -371
51
2011
Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report
B Coudert , A Anthoney , W Fiedler , J.P Droz
European Journal of Cancer 37 ( 17) 2194 -2198
68
2001
It's time for chronotherapy!
B Coudert , C Focan , E Donato di Paola , F Lévi
European Journal of Cancer 38 ( 4) 50 -53
14
2002
Abstract P5-17-04: Metastatic inflammatory breast cancer: Clinical features and outcomes in the national, multicentric, real-life ESME cohort
A Monneur , F Bertucci , A Lardy-Cleaud , P Augereau
Cancer Research 79
2019
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial
Xavier Pivot , Gilles Romieu , Marc Debled , Jean-Yves Pierga
The Lancet 393 ( 10191) 2591 -2598
105
2019
p53 gene alterations are associated with a decreased responsiveness to neoadjuvant chemotherapy in human breast cancer.
S LizardNacol , B Coudert , J Riedinger , P Fargeot
International Journal of Oncology 10 ( 6) 1203 -1207
7
1997
Nilutamide pneumonitis: a report on eight patients.
P Pfitzenmeyer , P Foucher , F Piard , B Coudert
Thorax 47 ( 8) 622 -627
41
1992
Preliminary results of a randomized study on first and second line chemotherapy strategy in stage IV non-small cell lung cancer (NSCLC), assessing docetaxel (D) and cisplatin (C) until progressive disease (PD) then vinorelbine (V) versus V-C until PD then D
J Douillard , R Gervais , H Lacroix , A Le Groumellec
Lung Cancer 29 ( 1) 91 -92
2
2000
Early whole brain concomitant radiotherapy-chemotherapy for non-small cell lung cancer (NSCLC) brain metastases. A phase 2 study
C Ngo Quy , M.-A Haller , A Darut-Jouve , G Jolimoy
Lung Cancer 29 ( 1) 100 -101
2000
Intérêt clinique du calcul des pentes de variation du CA 125 pour la surveillance biologique des tumeurs épithéliales ovariennes
J.M. Riedinger , S Lizard , B Coudert , I Barillot
Immuno-analyse & Biologie Spécialisée 14 ( 4) 244 -250
1999
Évaluation clinique du cancer associated serum antigen (CASA) comme marqueur tumoral des cancers ovariens : comparaison avec le CA 125
JM Riedinger , S Basiletti , S Lizard , F Mayer
Immuno-analyse & Biologie Specialisee 16 ( 3) 172 -182
2001
The Personalised Reimbursement Models (Prm): Real World Data Collection to Provide Innovative Pricing Solutions in France
A Doly , B Coudert , P Cottu , J Manson
Value in Health 20 ( 9)
1
2017
Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
C Massard , J-J Voigt , A Laplanche , S Culine
British Journal of Cancer 97 ( 11) 1959 -1959
43
2007